CNS Pharmaceuticals holders approve 650,000-share Equity Plan increase; six directors elected at annual meeting

CNS Pharmaceuticals, Inc.

Stockholders approved amending the 2020 Equity Plan to add 650,000 shares, raising total shares authorized for issuance to 765,061 from 115,061; vote was 96,953 for, 8,128 against, 35 abstain.
Rami Levin, Amy Mahery, Faith Charles, Bettina Cockroft, Michal Fisher and Jeffrey Keyes elected directors to serve until the 2027 annual meeting; each received between 100,524 and 102,460 votes for.
MaloneBailey, LLP ratified as independent registered public accounting firm for the year ending December 31, 2026: 637,228 for, 30,874 against, 89 abstain.
Advisory say-on-pay resolution approved with 98,103 for and 6,682 against; adjournment-of-meeting proposal authorized 622,421 for vs 45,635 against.
Annual meeting held September 30, 2026 with 668,188 shares (45.72%) present by proxy or in person, constituting a quorum; 1,461,449 shares outstanding at the August 10, 2026 record date.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.